Patient Support Services Contact Us
Image: Coherus Investors

News

04/20/21
Coherus received $50 million from sale of 2,491,998 shares at $20.06 per share REDWOOD CITY, Calif. , April 20, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced the closing of the sale of Coherus common stock to Junshi Biosciences.
03/03/21
- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China , and REDWOOD CITY, Calif. , March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc.
02/25/21
REDWOOD CITY, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. 41 st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m.
02/24/21
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 -  - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year -  - Pipeline progress with CHS-1420 (adalimumab biosimilar) BLA
02/18/21
REDWOOD CITY, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021.
02/17/21
REDWOOD CITY, Calif. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira®
02/16/21
REDWOOD CITY, Calif. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that Chief Financial Officer Jean-Frédéric Viret, Ph.D. will resign from Coherus effective March 7, 2021 to pursue another opportunity.
02/02/21
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic
02/01/21
- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody - First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation - Options to PD-1 combination agents, TIGIT and IL-2,
01/22/21
REDWOOD CITY, Calif. , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 60,000 shares
01/07/21
REDWOOD CITY, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board of Directors effective January 5, 2021 .  “We are excited to welcome Alan and Mark to the Coherus
01/05/21
REDWOOD CITY, Calif. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. EST / 7:50 a.m. PST .